Brokerage firm H.C. Wainwright Reiterates its rating on Vascular Biogenics Ltd(VBLT). In a research note issued to the investors, the brokerage major Maintains the price-target to $11 per share. The shares have been rated Buy. The rating by the stock financial advisor at H.C. Wainwright was issued on Mar 28, 2017 in a research report to their Investors and Clients.
Vascular Biogenics Ltd (VBLT) made into the market gainers list on Fridays trading session with the shares advancing 1.80% or 0.1 points. Due to strong positive momentum, the stock ended at $5.65, which is also near the day’s high of $5.8999. The stock began the session at $5.75 and the volume stood at 1,37,955 shares. The 52-week high of the shares is $7.58 and the 52 week low is $3.03. The company has a current market capitalization of $152 M and it has 2,68,90,926 shares in outstanding.
Vascular Biogenics Ltd(VBLT) last announced its earnings results on Mar 27, 2017 for Fiscal Year 2016 and Q4.Earnings per share were $-0.17.
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery development and commercialization of first-in-class treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. The Company is developing VB-111 the lead oncology product candidate from its VTS platform technology which is a gene-based biologic for the treatment of solid tumor indications with clinical programs in recurrent glioblastoma (rGBM) thyroid cancer and ovarian cancer. The Company is also conducting a program targeting anti-inflammatory diseases based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules developed by the Company that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation.